The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A multicenter, randomized, double-blind, phase III study of ramucirumab (IMC-1121B; RAM) and best supportive care (BSC) versus placebo (PBO) and BSC as second-line treatment in patients (pts) with hepatocellular carcinoma (HCC) following first-line therapy with sorafenib (SOR).
Andrew X. Zhu
Consultant or Advisory Role - Abbott Laboratories; Bristol-Myers Squibb; Eisai; Exelixis; Pfizer; Sanofi
Research Funding - Bayer; ImClone Systems; Novartis
Ian Chau
Consultant or Advisory Role - ImClone Systems
Jean-Frédéric Blanc
Honoraria - Bristol-Myers Squibb; ImClone Systems
Takuji Okusaka
Honoraria - Lilly
Research Funding - Lilly
Maria Rojas
Employment or Leadership Position - ImClone Systems
Stock Ownership - Lilly
Ling Yang
Employment or Leadership Position - ImClone Systems
Stock Ownership - Lilly
Ingo Von Broen
Employment or Leadership Position - ImClone Systems
Stock Ownership - Lilly